CT引导RFA尿路高排泄方案治疗内生性肾癌长期结局
本研究回顾性纳入61例经病理证实的肾内生性肾细胞癌患者,均在CT引导下接受射频消融,术中静脉注射呋塞米并输注生理盐水,形成尿路高排泄状态。中位随访54个月,5年局部肿瘤进展无复发生存率为96.7%,术后eGFR较术前显著下降但未出现重度肾功能恶化。结果显示该方案对内生性肾癌具有良好的肿瘤学结局和可接受的肾功能结局。
要点
- CT引导RFA术中采用呋塞米加生理盐水尿路高排泄方案,5年局部无进展生存率可达96.7%
- 术前eGFR 60–90 mL/min/1.73m²者术后约27.6%降至60以下,报告随访肾功能时应关注此类患者
- 主要并发症为输尿管肾盂连接部狭窄,发生率1.6%,阅片随访时注意集合系统改变
核心结论
- CT引导下射频消融联合尿路高排泄方案治疗内生性肾细胞癌,可获得良好的长期肿瘤控制结局与可接受的肾功能结局
研究设计与样本
- 单臂回顾性研究,纳入2014年6月至2021年3月61例经病理证实的内生性肾细胞癌患者
- 所有患者接受CT引导下经皮射频消融,消融开始前静脉注射呋塞米,消融过程中持续静脉输注生理盐水
- 中位RENAL肾肿瘤评分10分,范围7–11分
- 随访36–109个月,中位54个月,平均58个月
- 采用Kaplan-Meier法计算5年局部肿瘤无进展生存率,配对t检验比较消融前后eGFR
关键影像表现/征象
- 肿瘤为内生性生长,中位RENAL肾肿瘤评分为10分,影像上属解剖结构复杂的高分值内生性病灶
- 随访中出现局部肿瘤进展的2例患者在影像复查中可见消融区边缘或邻近区域新发强化或增大
- 1例主要并发症为输尿管肾盂连接部狭窄,影像上可表现为集合系统扩张积水
诊断标准与关键数值
- 5年局部肿瘤无进展生存率为96.7%(59/61)
- 消融前eGFR为86.5±18.2 mL/min/1.73 m²,消融后为77.0±19.5 mL/min/1.73 m²,P<.001
- 术前eGFR为60–90 mL/min/1.73 m²的29例患者中,8例(27.6%)术后eGFR降至60 mL/min/1.73 m²以下
- 术前eGFR≥90 mL/min/1.73 m²的26例患者中,无一例术后eGFR降至60 mL/min/1.73 m²以下
- 主要并发症发生率为1.6%,具体为输尿管肾盂连接部狭窄
临床应用与阅片要点
- 对高RENAL评分的内生性肾癌,CT引导RFA配合呋塞米及生理盐水尿路高排泄方案是一种可考虑的治疗选项
- 术后影像随访应重点观察消融区边缘有无强化或增大,以早期发现局部肿瘤进展
- 术后随访除肿瘤控制外,应常规监测eGFR,尤其对术前eGFR在60–90 mL/min/1.73 m²的患者
- 报告术后CT或MRI时,应注意评估集合系统有无狭窄及继发积水等主要并发症
局限性
- 本研究缺乏与未使用利尿剂或肾盂灌注等其他保护方案的直接对照
- 单臂回顾性设计,选择性偏倚及混杂因素影响难以排除
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To retrospectively assess how urine-hyperexcreting procedures influence oncologic and functional long-term outcomes of endophytic renal cell carcinomas (RCCs) treated with percutaneous radiofrequency ablation (RFA).
METHODS: Between June 2014 and March 2021, 61 patients underwent CT-guided RFA to treat a histologically proven endophytic RCC. The median RENAL nephrometry score was 10 (7-11). Furosemide was intravenously injected just prior to beginning ablation cycles and normal saline was intravenously infused during RFA procedures. All were followed for 36-109 months (median, 54 months; mean, 58 months). A 5-year local tumor progression (LTP)-free survival rate was calculated with Kaplan-Meier Analysis. Estimated glomerular filtration rates (eGFR) before and after RFA were compared with a paired-t-test. The number of patients with an eGFR decreases to less than 60 mL/min/1.73m2 were assessed following RFA. The types or rates of major complication were recorded.
RESULTS: A 5-year LTP-free survival rate was 96.7% (59/61). Two patients had LTP, which were treated with additional RFA or surgery. Pre-RFA and post-RFA eGFRs were 86.5 ± 18.2 mL/min/1.73 m2 and 77.0 ± 19.5 mL/min/1.73 m2, respectively (P < .001). Among 29 patients with eGFR of ≥60 and <90 mL/min/1.73 m2, 8 (27.6%) had eGFRs decreased under 60 mL/min/1.73 m2; none of the 26 patients with ≥90 mL/min/1.73 m2 showed such a decrease. One patient had a major complication (1.6%) which was uretero-pelvic stricture.
CONCLUSIONS: CT-guided RFA using a urine-hyperexcreting protocol contributes to good oncologic and acceptable functional long-term outcomes of endophytic RCCs.
ADVANCES IN KNOWLEDGE: CT-guided RFA using a urine-hyperexcreting protocol has the potential to safely treat endophytic RCCs in patients with normal renal function but needs further investigation to compare diuretic group and non-diuretic or pyeloperfusion group.
引用
- Park. CT-guided RFA using a urine-hyperexcreting protocol in treating endophytic RCC: long-term outcomes in a single-arm study. Br J Radiol. 2026. PMID: 42500987. doi:10.1093/bjr/tqag107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。